The first human trial of gene editing technology to treat a rare disease in the US has returned disappointing results, researchers at Sangamo Therapeutics announced today.
Gene-editing has been hailed as the best hope to treat inherited disorders.
Sangamo's trial used proteins that bind to targeted segments of DNA to deliver gene therapy to three patients with a rare genetic disorder that disrupts their ability to process certain sugars, causing damaging build-up in the brain, bones and more.
But a year and nine months after the trial's start, the patients' levels of harmful sugars have stayed effectively the same, casting a disappointing shadow of doubt over the prospects for 'fixing' the genome.
Brian Madeux (center, file image) was among the first people to have his genome edited as part of the first US human trial to attempt to cure two genetic diseases. His genes were successfully edited, but the treatment has so far done little to change markers of the disease, according to preliminary findings of Sangamo Therapeutics trials released today
More than 6,000 deadly or debilitating diseases lurk in the genetic code.
Until very recently, all that could be done for people with these diseases was to treat their symptoms - there was no way to cure or reverse these conditions.
But the theory - and the hope - is that if we can alter the genes that carry these diseases, we could edit mutations out of existence.
One of the earliest, most promising methods for doing so uses so-called zinc finger nucleases (also referred to as simply zinc fingers, or ZFNs).
Zinc fingers are a fuse of two compounds that can be engineered to seek out and cut specific segments of DNA.
The latest advancements for gene-editing use the Nobel Prize-winning CRISPR technology, but the method is too new for human trials.
Scientists at Sangamo used these to target genes that code for two related disorders, mucopolysaccharidosis types I and II (MPS I and MPS II).
MPS I causes Hurler syndrome, a deficiency of an enzyme that, in healthy people, breaks down complex sugar chains called glycosaminoglycans (GAGs).
In those with Hurler syndrome, GAGs instead build up in the